Polygemcitabine nanogels with accelerated drug activation for cancer therapy

Chem Commun (Camb). 2019 Jun 4;55(46):6603-6606. doi: 10.1039/c9cc01506j.

Abstract

To overcome the slow activation of gemcitabine, we synthesized a DNA-like polygemcitabine (Ge10) strand through solid-phase synthesis, which not only undergoes rapid intracellular degradation to generate active gemcitabine derivatives, but can also self-assemble into nanogels through molecular recognition, rendering them as promising self-delivered nanodrugs for cancer therapy.

MeSH terms

  • A549 Cells
  • Animals
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents / toxicity
  • Apoptosis
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / chemical synthesis
  • Deoxycytidine / pharmacology
  • Deoxycytidine / therapeutic use
  • Deoxycytidine / toxicity
  • Gels / chemical synthesis
  • Gels / pharmacology
  • Gels / therapeutic use*
  • Gels / toxicity
  • Gemcitabine
  • Humans
  • Mice, Nude
  • Nanoparticles / therapeutic use
  • Nanoparticles / toxicity
  • Neoplasms / drug therapy*
  • Polymers / chemical synthesis
  • Polymers / pharmacology
  • Polymers / therapeutic use*
  • Polymers / toxicity
  • Prodrugs / chemical synthesis
  • Prodrugs / pharmacology
  • Prodrugs / therapeutic use*
  • Prodrugs / toxicity
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Gels
  • Polymers
  • Prodrugs
  • Deoxycytidine
  • Gemcitabine